A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE005 (FRA) · Dr. Muller
consented 2023-03-16
AEs
3
Serious
1
Dropout signal
–
Adverse events
severe
serious
assessed
Grade 4 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-05-12 (study day 42); relationship: Y; serious criteria: life-threatening
mild
assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-07-02 (study day 93); relationship: not assessed
mild
assessed
Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-11-06 (study day 220); relationship: N
Data queries
No data queries.